comparemela.com
Home
Live Updates
Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19 : comparemela.com
Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19
In this randomised, double blind, 2x2 factorial placebo-controlled trial, Dr David Lowe and colleagues investigate the impact of early antiviral therapy in COVID-19.
Related Keywords
Ikeji ,
Kagoshima ,
Japan ,
Canada ,
United Kingdom ,
London ,
City Of ,
British ,
Norgen Biotek ,
United Kingdom Medical Research Council ,
Rosetrees Foundation ,
Trial Steering Committee ,
University Of Birmingham ,
University College London Hospital ,
John Black Foundation ,
National Health Service ,
Novartis ,
Astrazeneca ,
Wales Research Ethics Committee ,
Allergan ,
Wellcome ,
Bristol Myers Squibb ,
Fujifilm Toyama Chemical Co ,
British Society For Antimicrobial Chemotherapy ,
Data Monitoring Committee ,
Gedeon Richter ,
Medience Corporation ,
Urgent Public Health ,
Novo Nordisk ,
Coronavirus Disease ,
Severe Acute Respiratory Syndrome Coronavirus ,
Creative Commons Attribution License ,
Supporting Information ,
Clinical Director ,
Clinical Trials Unit ,
Blood Cancer United Kingdom ,
British Society ,
Abbott Singapore ,
Wellcome Trust ,
Great Ormond Street Hospital ,
Independent Data Monitoring Committee ,
Middle East Respiratory Syndrome ,
Urgent Public ,
Acute Respiratory Syndrome Coronavirus ,
Royal Free Hospital ,
Fujifilm Toyama Chemical ,
Agile Lighthouse ,
Professor Chris Frost ,
Mak Wenyao ,
Viral Load ,
Sars Cov 2 ,
Covid 19 ,
Protease Inhibitor Therapy ,
Antiviral Therapy ,
Virus Testing ,
Saliva ,
Antibodies ,
comparemela.com © 2020. All Rights Reserved.